Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03702036|
Expanded Access Status : Available
First Posted : October 10, 2018
Last Update Posted : October 10, 2018
|Condition or disease||Intervention/treatment|
|Solid Tumours||Drug: molibresib|
Investigational Product GSK525762 is an orally bioavailable small molecule that is a potent inhibitor of the binding of BET proteins to acetylated histones. Binding of GSK525762 induces squamous differentiation and inhibits proliferation of patient-derived NMC cell lines both in culture and in murine xenografts.
Compassionate use access to molibresib is restricted to patients with confirmed diagnosis of NUT Midline Carcinoma.
|Study Type :||Expanded Access|
|Expanded Access Type :||Individual Patients|
|Official Title:||Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma|
- Drug: molibresib
molibresib 20 mg will be supplied for compassionate use for the identified individual subject.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03702036
|Contact: US GSK Clinical Trials Call Center||877-379-3718||GSKClinicalSupportHD@gsk.com|
|Study Director:||GSK Clinical Trials||GlaxoSmithKline|